License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended March 31,
Partner	Drug or Drug Candidate	2020		2019
Bristol-Myers Squibb Company	Bempegaldesleukin	$	25,000	$	—
Eli Lilly and Company	NKTR-358	1,259		2,500
Amgen, Inc.	Neulasta®	1,250		1,250
Other		6		454
License, collaboration and other revenue		$	27,515	$	4,204

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March 31, 2020 (in thousands):

	Three Months Ended March 31, 2020
Deferred revenue—December 31, 2019	$	8,071
Recognition of previously unearned revenue	(2,510)
Deferred revenue—March 31, 2020	$	5,561